CEO Perspective: A defining moment for Cellular Intelligence
Today we’re sharing a defining moment for Cellular Intelligence. We have entered into an agreement with Novo Nordisk to acquire STEM-PD, a Phase 2-ready allogeneic cell therapy program for Parkinson’s disease. In connection with the transaction, Novo Nordisk is also making a strategic investment in Cellular Intelligence.
The program has completed Phase 1/2 dosing, has an FDA-cleared IND for Phase 2, Fast Track Designation, and early clinical data with PET evidence of graft function and supportive quality-of-life patterns at 12 months. The Phase 1/2 trial was also highlighted by Nature Medicine as one of the 11 clinical trials that will shape medicine in 2024.
This is more than an asset acquisition.
This deal catapults CI into a Phase 2-ready clinical company and, just as importantly, gives us the clearest possible demonstration engine for our AI-native platform.
It marks the beginning of an AI-native era for cell replacement therapy, one where biology is no longer destiny, but design.
Cell therapy has long held extraordinary promise, but it has also been constrained by complexity. Manufacturing is hard. Biology is context-dependent. Protocol development remains too empirical, too slow, and too dependent on trial and error.
At Cellular Intelligence, we believe this can change.
We are building an AI-native, fully integrated therapeutics company. The same platform that learns how cells respond to signals can help design better protocols, improve manufacturability, optimize functional dose, and deepen our understanding of how development decisions connect to clinical outcomes.
STEM-PD gives us the ideal proving ground for that vision.
It brings together a clinical-stage program in Parkinson’s disease, an area of significant unmet need, with a platform designed to make cell therapy more predictive, scalable, and controllable.
Our central thesis is simple: cell therapy can move from an empirical process into a predictive engineering discipline.
This is the company we set out to build: the defining AI-native, fully integrated cell therapy company.
We are grateful to Novo Nordisk for their trust and confidence, to our investors and advisors for their continued belief, and to the Cellular Intelligence team for the relentless work that made this possible.
This is an extraordinary step forward for the company, for our platform, and most importantly, for the future of cell therapy and the patients it has the potential to one day serve.
Micha Breakstone, Co-Founder & CEO
STEM-PD is an investigational therapy; its safety and efficacy have not been established.